ZIM
ADPT icon

Zacks Investment Management’s Adaptive Biotechnologies ADPT Stock Holding History

Zacks Investment Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-85,627
Closed -$756K – 639
2023
Q1 		$756K Buy
85,627
+3,928
+5% +$34.6K 0.01% 404
2022
Q4 		$624K Sell
81,699
-12,806
-14% -$99.6K 0.01% 420
2022
Q3 		$673K Buy
+94,505
New +$890K 0.01% 395

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Zacks Investment Management's ADPT Position: Q2 2023 in Review

Zacks Investment Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2023, closing a stake of 85,627 shares — an estimated $756K sold.

Zacks Investment Management first reported a position in ADPT in Q3 2022 and held it in 3 quarters. The position peaked at $756K in Q1 2023. 210 funds tracked by Wall St. Rank hold ADPT as of Q2 2023.

  • Zacks Investment Management reported no remaining Adaptive Biotechnologies position as of Q2 2023 after selling out during the quarter.
  • Zacks Investment Management sold 85,627 Adaptive Biotechnologies shares in Q2 2023, an estimated $756K.
  • Zacks Investment Management first reported a position in Adaptive Biotechnologies in Q3 2022 and held it in 3 quarters.
  • Zacks Investment Management's Adaptive Biotechnologies position peaked at $756K in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2023.

Based on Zacks Investment Management's 13F filing for Q2 2023, filed 15 Aug 2023.